Dr. Reddys Laboratories Ltd.

Dr Reddy’s Laboratories has launched Gemcitabine for Injection (200 mg/vial and 1 g/vial), a bioequivalent generic version of Gemzar in the US market, following the approval by the United States Food & Drug Administration (USFDA) of Dr Reddy’s Abbreviated New Drug Application (ANDA) for Gemcitabine for injection.

The Gemzar brand had US sales of about $634 million for the most recent twelve months ending May 31, 2011. The company’s Gemcitabine for Injection 200mg/vial and 1 g/vial strengths are available in single-use vials.

Dr Reddys, a global pharmaceutical company, has a global presence in more than 100 countries, with subsidiaries in the US, UK, Russia, Germany and Brazil; joint ventures in China, South Africa and Australia; representative offices in 16 countries and third-party distribution set ups in 21 countries.